Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Biol Blood Marrow Transplant 2019 03 5;25(3):e89-e97. Epub 2018 Nov 5.

The Transplant & Cellular Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183069
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445685PMC
March 2019
8 Reads

Publication Analysis

Top Keywords

immune profiling
12
residual disease
12
minimal residual
12
disease immune
8
intergroup workshop
8
workshop minimal
8
ctn myeloma
8
myeloma intergroup
8
second annual
8
bmt ctn
8
american society
4
ash abstracts
4
network bmt
4
society hematology
4
workshop presentations
4
summarizes workshop
4
profiling convened
4
convened december
4
december 2017
4
presentations well
4

Similar Publications